Copyright
©The Author(s) 2021.
World J Gastroenterol. Jun 21, 2021; 27(23): 3327-3341
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3327
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3327
Table 1 Comparative analysis of hepatic tuftelin 1 immunohistochemical staining and expressing intensity between hepatocellular carcinoma and their para-cancerous tissues
Group | n | TUFT1 | χ2 value | P value | TUFT1 score | Z value | P value | ||||
Neg. | Pos. | 0 | 1 | 2 | 3 | ||||||
HCC | 132 | 17 | 115 | 18.563 | < 0.001 | 17 | 49 | 55 | 11 | 4.911 | < 0.001 |
Non-HCC | 132 | 47 | 85 | 47 | 54 | 23 | 8 |
Table 2 Relationship between tuftelin 1 and clinicopathological characteristics in hepatocellular carcinoma patients
Group | n | TUFT1 expression | Pearson χ2 | P value | |
Low | High | ||||
AFP (ng/mL) | 2.901 | 0.089 | |||
< 20 | 28 | 18 | 10 | ||
≥ 20 | 104 | 48 | 56 | ||
HBsAg | 3.300 | 0.069 | |||
Neg. | 12 | 9 | 3 | ||
Pos. | 120 | 57 | 63 | ||
HBeAg | 4.080 | 0.043 | |||
Neg. | 87 | 49 | 38 | ||
Pos. | 45 | 17 | 28 | ||
Tumor size (cm) | 9.388 | 0.002 | |||
< 3 | 26 | 20 | 6 | ||
≥ 3 | 106 | 46 | 60 | ||
Differentiation degree | 3.013 | 0.083 | |||
Well-Med. | 19 | 13 | 6 | ||
Poor | 113 | 53 | 60 | ||
Vascular invasion | 14.885 | < 0.001 | |||
With | 58 | 18 | 40 | ||
Without | 74 | 48 | 26 | ||
Ascites | 5.940 | 0.015 | |||
With | 32 | 10 | 22 | ||
Without | 100 | 56 | 44 | ||
TNM staging | 13.516 | < 0.001 | |||
I-II | 59 | 40 | 19 | ||
III-IV | 73 | 26 | 47 |
Table 3 Univariate and multivariate analysis of tuftelin 1 in the prognosis of hepatocellular carcinoma
Group | Univariate analysis | Multivariate analysis | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
TUFT1 expression, high vs low | 3.026 | 1.927-4.752 | < 0.001 | 1.743 | 1.044-2.910 | 0.034 |
AFP (ng/mL), ≥ 20 vs < 20 | 1.866 | 1.066-3.266 | 0.027 | 1.482 | 0.835-2.630 | 0.178 |
HBsAg, pos. vs neg. | 1.495 | 0.652-3.431 | 0.339 | |||
HBeAg, pos. vs neg. | 1.670 | 1.084-2.574 | 0.019 | 1.070 | 0.659-1.739 | 0.784 |
Tumor size (cm), ≥ 3 vs < 3 | 3.680 | 1.837-7.370 | < 0.001 | 2.235 | 1.043-4.485 | 0.039 |
Differentiation degree, Poor vs well-med. | 1.642 | 0.869-3.100 | 0.123 | |||
Vascular invasion, with vs without | 3.297 | 2.133-5.094 | < 0.001 | 2.018 | 1.186-3.434 | 0.010 |
Ascites, with vs without | 2.592 | 1.648-4.076 | < 0.001 | 1.929 | 1.177-3.161 | 0.009 |
TNM staging, III-IV vs I-II | 2.411 | 1.532-3.796 | < 0.001 | 1.110 | 0.614-2.005 | 0.731 |
- Citation: Wu MN, Zheng WJ, Ye WX, Wang L, Chen Y, Yang J, Yao DF, Yao M. Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth. World J Gastroenterol 2021; 27(23): 3327-3341
- URL: https://www.wjgnet.com/1007-9327/full/v27/i23/3327.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i23.3327